Evidence map›Paper›PMID 41337590›Full record

ArticleScience advances2025

Virus-induced APOBEC3 transmutagenesis in bladder cancer initiation.

George H Hatton, Sally R James, Andrew S Mason, Richard T Gawne, Helena Vogel, Karen Hogg, Parisa Boukani, Gemma Swinscoe, Anjum Khan, Matthew Welberry Smith and 8 more

Abstract read
In one paragraph

Article in Science advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

George H HattonJack Birch Unit for Molecular Carcinogenesis, Department of Biology and York Biomedical Research Institute, University of York, Heslington, York, UK.ORCID 0009-0001-6321-7229
Sally R JamesBioscience Technology Facility, Department of Biology, University of York, Heslington, York YO10 5DD, UK.ORCID 0000-0003-2701-9724
Andrew S MasonJack Birch Unit for Molecular Carcinogenesis, Department of Biology and York Biomedical Research Institute, University of York, Heslington, York, UK.ORCID 0000-0002-8222-3974
Richard T GawneJack Birch Unit for Molecular Carcinogenesis, Department of Biology and York Biomedical Research Institute, University of York, Heslington, York, UK.ORCID 0009-0004-0886-0870
Helena VogelLaboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.ORCID 0000-0001-8002-646X
Karen HoggBioscience Technology Facility, Department of Biology, University of York, Heslington, York YO10 5DD, UK.ORCID 0000-0001-7015-5102
Parisa BoukaniLaboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.ORCID 0009-0000-0150-8904
Gemma SwinscoeFaculty of Biological Sciences, School of Molecular and Cellular Pathology, University of Leeds, Leeds, UK.ORCID 0000-0003-0595-3460
Anjum KhanFaculty of Biological Sciences, School of Molecular and Cellular Pathology, University of Leeds, Leeds, UK.ORCID 0000-0001-6432-6999
Matthew Welberry SmithFaculty of Biological Sciences, School of Molecular and Cellular Pathology, University of Leeds, Leeds, UK.ORCID 0000-0002-9018-6827
Michael A CarpenterDepartment of Biochemistry and Structural Biology, The University of Texas at San Antonio, University of Texas, San Antonio, TX, USA.ORCID 0000-0001-9524-5323
Omar MasoodLeeds Kidney Unit, St. James's University Hospital, Leeds Teaching Hospitals NHS Trust, Leeds, UK.ORCID 0009-0001-1763-4793
Iñigo MartincorenaCancer, Ageing and Somatic Mutation, Wellcome Sanger Institute, Hinxton, UK.ORCID 0000-0003-1122-4416
Andrew MacdonaldFaculty of Biological Sciences, School of Molecular and Cellular Pathology, University of Leeds, Leeds, UK.ORCID 0000-0002-5978-4693
Reuben S HarrisDepartment of Biochemistry and Structural Biology, The University of Texas at San Antonio, University of Texas, San Antonio, TX, USA.ORCID 0000-0002-9034-9112
Gabriel J StarrettLaboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.ORCID 0000-0001-5871-5306
Jennifer SouthgateJack Birch Unit for Molecular Carcinogenesis, Department of Biology and York Biomedical Research Institute, University of York, Heslington, York, UK.ORCID 0000-0002-0135-480X
Simon C BakerJack Birch Unit for Molecular Carcinogenesis, Department of Biology and York Biomedical Research Institute, University of York, Heslington, York, UK.ORCID 0000-0002-2755-6012

Funding

PROJECT 3 – BIOLOGY OF DNA DEAMINASES IN CANCERP01CA234228 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Michael Allen Carpenter · 2019 to 2026
$14.5M
NCI NIH HHS P01 CA234228
6 · The paper itself

Abstract

Carcinogenesis in human urothelium is driven by a high burden of mutations caused by the antiviral "APOBEC3" (apolipoprotein B mRNA editing enzyme, catalytic subunit-like 3) cytosine deaminase enzymes; however, there is no established viral etiology. BK polyomavirus (BKPyV) is a ubiquitous childhood infection that persists in the kidney during adulthood and is frequently detected in urine. Chronic BKPyV infections of normal human urothelium induced an innate response, including apical extrusion of infected cells. Local paracrine interferon signaling induced APOBEC3 expression in both infected and juxtaposed bystander cells, leading to acquisition of hallmark APOBEC3-mediated mutational signatures that recapitulated the variation in mutational character found in patients with muscle-invasive bladder cancer. In our model for urothelial carcinogenesis, uninfected bystander cells witnessing BKPyV infection become APOBEC3 damaged, escape extrusion, and acquire hypermutable advantage. "Transmutagenesis" explains how cells proximal to infected neighbors acquire cancer-initiating mutations. This hypothesis for how urothelial cancers can develop as APOBEC3 signature rich, while remaining virus-negative, suggests that a large proportion of urothelial carcinomas may be preventable by antiviral intervention.

Indexed as

BK VirusCytidine DeaminaseMutationPolyomavirus InfectionsTumor Virus InfectionsUrinary Bladder NeoplasmsAPOBEC DeaminasesCarcinogenesisHumansUrotheliumAPOBEC3 proteins, humanAPOBEC DeaminasesCytidine Deaminase

Identifiers

PMID41337590
PMCPMC12674112

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.